Introduction
============

Hepatocellular carcinoma (HCC), with estimated 782,000 new cases global incidence every year, caused nearly 746,000 deaths worldwide annually [@B1]. However, the high risk of metastasis and recurrence after operation for patients with HCC is high [@B2]-[@B3]. The high rate of recurrence after complete resection is a significant prognostic factor, with a cumulative recurrence rate of 50% and 60% at 3 years and 60% and 80% at 5 years [@B4]-[@B7]. To date, a variety of predictive biomarkers have been shown to predict clinical outcomes in HCC patients. For example, Chuma M found that HSP70 could be a sensitive indicator for the differential diagnosis of early HCC from precancerous lesions or noncancerous livers [@B8]~.~In addition, Jiang suggested the possible oncogenic and prognostic role of Galectin-3 in hepatocellular carcinoma [@B9]. Due to complicated detective equipment and expensive costs, accurate, fast, as well as convenient predictive biomarkers for the identification of patients with high risk of metastasis and recurrence are urgently needed.

Abnormal lipid metabolism is considered to be related to several cancers [@B10]. In previous research, reduced pre-operative HDL-C levels were linked with poor survival in NSCLC patients [@B11]. Additionally, low HDL-C levels are also associated with increased post-menopausal breast cancer risk [@B12]-[@B15]. However, the role of lipid metabolism in cancer development has not been fully explored. Some recent studies have illustrated the plasma lipid profiles of hepatocellular carcinoma patients: Ahaneku et al [@B16] found that in HCC patients, HDL-fraction levels, including HDL-phospholipids (HDL-PL), HDL-cholesterol (HDL-C) and the ratio of HDL-C/HDL-PL, in HCC patients were significantly lower than controls. Motta et al [@B17] recruited 40 HCC patients, and evaluated their LDL-C and HDL-C levels. In HCC patients, the LDL-C levels were significantly lower than controls, but the HDL-C levels were not statistically significantly different from those of the controls. Chen X et al [@B18] reported that there was a significant difference between high and low levels of serum TC that could be used to evaluate pancreatic carcinoma risk in Europeans. However, there is little evidence about the impact on lipid profiles in clinical outcomes with hepatocellular carcinoma patients.

The current study aimed to explore the predictive role of the lipid profile on overall survival (OS) and disease-free-survival (DFS) in HCC patients undergone complete resections.

Methods
=======

Patient Selection
-----------------

A total of 1411 HCC patients who had undergone complete surgical resection at Sun Yat-sen University Cancer Center from 2001 to 2010 were collected and reviewed in the present study. Approval was obtained from the Ethics Committee of the Sun Yat-sen University Cancer Center (Guangdong, China). Written informed consent was received from each patient. All patients met the following eligibility criteria: (1) all patients had pathologically confirmed hepatocellular carcinoma; (2) without cancer history; (3) no treatment before serum obtained; and (4) serum samples were collected before treatment, and the levels of LDL-C, HDL-C, TG, and CHO were tested using a Hitachi 7600-020 automatic biochemical analyzer. Clinical data, including the treatment strategy and the pathologically diagnosis, were obtained from the patients\' records. For the current study, all pathological diagnoses were confirmed by an independent experienced pathologist at Sun Yat-sen University Cancer Center. Histological types were determined from the World Health Organization classification criteria.

Patient follow-up
-----------------

All patients were followed-up in the outpatient department, and underwent physical examinations and laboratory tests every 3 months in the first 2 years, then every 6 months in the 3rd to 5th years, and every year for an extra 5 years or death, no matter which occurred first. The primary outcome of the present study was overall survival (OS), defined as the time from curative resection to the time of death. Relatively, the secondary outcome was disease-free survival (DFS), calculated from the date of radical operation to the date of disease recurrence or distant metastases diagnosed.

Statistical analysis
--------------------

The cut-off value of the lipid profile was established by receiver operating characteristic (ROC) curve statistical analyses. The Kaplan-Meier method and the log-rank test were used to calculate the survival curves. The risk factors for survival were identified by the Cox proportional hazards model. The associations between CHO, HDL-C levels and clinic pathological parameters were tested by chi-square test. *P* Values of less than 0.05 were considered statistical significant in all statistical approaches. Data analyses were performed with SPSS 18.0 (PASW Statistics 18) for Windows (SPSS Inc., Chicago, IL).

Results
=======

Patient Characteristics
-----------------------

After the eligibility review, 1411 HCC patients who underwent radical surgical resection were enrolled in the analysis, and their characteristics are presented in Table [1](#T1){ref-type="table"}. The median follow-up time was 79 months (range: 1 to 176 months). The median age at resection was 41 years (range: 5 to 78 years), and 1243 (88.1%) of the patients were males and 68 (11.9 %) were females. Staging was conducted according to the tumor-node -metastasis (TNM) classification for HCC (Union for International Cancer Control). 848 patients (60.1 %) were diagnosed with stage I disease, other 563 (39.9%) patients were diagnosed with stage II-III disease. A total of 1231 patients (87.2%) had hepatic B virus infection.

Cut-off determination of lipid metabolism
-----------------------------------------

After receiver operating curve (ROC) analysis, the optimal cutoff value for CHO was 4.420 mmol/L (AUC: 0.532 mmol/L, 95% CI: 0.502 - 0.562), 1.06 mmol/L for TG (AUC: 0.537 mmol/L, 95% CI: 0.507-0.567), 0.88 mmol/L for HDL (AUC: 0.542 mmol/L, 95% CI: 0.512 - 0.572), and 3.09 mmol/L for LDL (AUC: 0.501, 95% CI: 0.471 - 0.532).

The Correlation Between the CHO, HDL-C Levels and Other Clinical Characteristics
--------------------------------------------------------------------------------

The relationships between the clinicopathological features of HCC and CHO and HDL-C levels are summarized in Tables [2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}. The statistical analysis showed that the CHO level was significantly related with cirrhosis (P =0.047). However, there was no significant links between CHO levels and other clinicopathological parameters, including differentiation status, TNM stage, and BCLC stage (both P \> 0.05). The HDL-C level was significantly correlated with tumor size (P \<0.001), HBsAg (P =0.029), and BCLC stage (\<0.001).

The Prognostic Significance of Clinical Characteristics in Hepatocellular carcinoma
-----------------------------------------------------------------------------------

In univariate analyses, significant correlation between tumor number, size, AFP, tumor differentiation, TNM stage, BCLC stage, CHO and HDL-C levels and DFS and OS were detected. In multivariate analysis, we observed significant associations of tumor size, AFP, TNM stage, CHO, and HDL-C levels with OS (Table [4](#T4){ref-type="table"}). In addition, associations between tumor size, AFP, TNM stage and CHO levels with DFS were observed. The multivariate analysis was conducted based on age at resection, gender, HBsAg, gender, cirrhosis, AFP, tumor differentiation, tumor number, tumor size, TNM stage, BCLC stage, HDL-C level, CHO level, LDL-C level and TG level.

The Prognostic Significance of the Serum Lipid Profile in Hepatocellular carcinoma
----------------------------------------------------------------------------------

Among the 1411 patients, distant metastasis or local recurrence after a radical surgical resection was diagnosed in 345 of 520 (66.3%) patients with a CHO level ≤4.420 mmol/L and in 545 of 891 (61.2%) patients with a CHO level \> 4.420 mmol/L (P = 0.012). Regarding OS, there were 300 of 520 (57.7%) patients with a CHO level ≤ 4.420 mmol/L, and 449 of 891 (50.4%) patients with a CHO level \> 4.420 mmol/L (P=0.003) who occurred death. A decreased CHO level was significantly correlated with decreased OS (HR, 0.800; 95% CI, (0.691-0.926), P =0.003; Table [4](#T4){ref-type="table"}; Figure [1](#F1){ref-type="fig"}) and remained statistically different in multivariate analysis including tumor size, AFP, tumor differentiation, and TNM stage (HR, 0.831; 95% CI, 0.714-0.967, P=0.017; Table [4](#T4){ref-type="table"}). Patients with CHO levels ≤ 4.420 mmol/L presented with OS of 42 months. Conversely, patients with CHO level \> 4.420 mmol/L presented with OS of 62 months. In univariate analysis, a decreased CHO level was significantly linked with decreased DFS (HR, 0.844; 95% CI, 0.737-0.966, P=0.012) (Table [5](#T5){ref-type="table"}; Figure [2](#F2){ref-type="fig"}) and remained statistically different in multivariate analysis including tumor size, AFP, tumor differentiation, and TNM stage (HR, 0.850; 95% CI, 0.740-0.977, P=0.022) (Table [5](#T5){ref-type="table"}). Patients with CHO levels ≤ 4.420 mmol/L had a median DFS of 19 months. In a contrast patients with CHO levels \> 4.420 mmol/L presented with a median DFS of 26 months.

Local recurrence or distant metastasis after radical surgical resection was confirmed in 176 of 256 (68.7%) patients with an HDL-C level ≤0.88 mmol/L and in 714 of 1155 (61.8%) patients with an HDL-C level \> 0.88 mmol/L (P=0.002). Regarding OS, there were 161 of 256 (62.9%) patients with an HDL-C level ≤ 0.88 mmol/L, and 588 of 1155 (53.1%) patients with HDL-C levels \> 0.88 mmol/L (P\<0.01) who occurred death. In univariate analysis, a decreased HDL-C level was significantly associated with decreased OS (HR, 0.679; 95% CI, 0.570-0.808, P\<0.01; Table [4](#T4){ref-type="table"}; Figure [3](#F3){ref-type="fig"}) and remained statistically different in the multivariate analysis that included tumor size, AFP, tumor differentiation, and TNM stage (HR, 0.790; 95% CI, 0.658-0.948, P =0.011; Table [4](#T4){ref-type="table"}). Patients with HDL-C levels ≤ 0.88 mmol/L had a median OS of 31 months. In contrast, patients with HDL-C levels \> 0.88 mmol/L had a median OS of 61 months. In the univariate analysis, an increased HDL-C level was statistically linked with increased DFS (HR, 2.085; 95% CI, 1.271-3.422, P = 0.002; Table [5](#T5){ref-type="table"}; Figure [4](#F4){ref-type="fig"}). However, in the multivariate analysis, HDL levels were not statistically significant (Table [5](#T5){ref-type="table"}). Patients with HDL-C levels ≤ 0.88 mmol/L presented with a median DFS of 15 months, whereas patients with HDL-C levels \> 0.88 mmol/L had a median DFS of 26 months.

Discussion
==========

Due to the high rate of relapse after HCC resection, the risk factors for tumor relapse are worth studying and could help support the initiation of interventional measures earlier and improve the surveillance to reduce the rate of relapse and improve the quality of survival for patients with HCC [@B19]-[@B22]. Several studies have confirmed that abnormal lipid profiles associated with an increased risk of recurrence and decreased survival in several cancers, including HCC [@B23]-[@B24]. However, the present study enrolled a relatively large amount of Chinese patients to investigate the lipid profiles and HCC prognosis.

Approximately 80% of endogenous cholesterol is synthesized in the hepatocellular microsomes containing cholesterol synthase [@B25]-[@B26]. In chronic liver diseases and HCC, the metabolism and synthesis of cholesterol are damaged, which lead to a decrease in plasma cholesterol levels [@B27]-[@B28]. In our research, we found that having a lower CHO level results in a poor prognosis in HCC patients. Additionally, lower cholesterol levels are related to cirrhosis and not to cancer stages. Similar results have been described in patients with gastric cancer [@B29]. Decreased serum cholesterol concentration was also found in other cancers [@B30]-[@B31], which are probably associated with the increased metabolism of cholesterol by the tumor cells. Additionally, it is reported that the synthesis of cholesterol has been reduced in cancer patients [@B32], and moderate increase of serum cholesterol levels may be a protective factor on cancer mortality.

In current years, there is increasing evidence that HDL-C may be linked with the tumorigenesis and progression of cancers [@B33]. In the present study, we investigated the relation between HDL-C and hepatocellular carcinoma, and found that increased pre-operative plasma HDL-C levels were associated with increased DFS and OS after radical surgery.

From previous studies, two possible molecular mechanisms have suggested for the relation between HDL-C and the relapse of HCC and poor survival. One is that HDL-C remove redundant cholesterol from an intracellular pool to maintain normal cell cholesterol homeostasis. It was observed that serum HDL-cholesterol levels were negatively associated with cholesterol levels in the tumor tissues of patients [@B15]. Due to an increasing consumption and storage of cholesterol within tumor tissues during growth, it is potential to assume that lower HDL levels are linked with the increasing cholesterol metabolism in proliferating tissues.

Another mechanism includes HDL metabolism, which could be regulated by cytokines. Increased levels of HDL have been connected with decreased circulating levels of proinflammatory cytokines, such as interleukin 6(IL-6), IL-1, and tumor necrosis factor (TNF-α), whereas linked with elevated levels of anti-inflammatory cytokines, for example IL-10 [@B34]. These proinflammatory cytokines are thought to improve cell proliferation and inhibit apoptosis [@B35].

Our study indicated that CHO and HDL-C levels are significantly related with HCC generation and development, and might be helpful in the identification and follow-up of high-risk HCC patients. CHO and HDL-C levels at diagnosis are considered as prognostic factors for HCC.
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![Kaplan-Meier curve for overall survival regarding low vs high CHO levels (P =0.003).](jcav07p0626g001){#F1}

![Kaplan-Meier curve for disease-free survival regarding low vs high CHO levels (P =0.012).](jcav07p0626g002){#F2}

![Kaplan-Meier curve for overall survival regarding low vs high HDL-C levels (P \<0.01).](jcav07p0626g003){#F3}

![Kaplan-Meier curve for disease-free survival regarding low vs high HDL-C levels (P =0.002).](jcav07p0626g004){#F4}

###### 

Characteristics of patients.

  Characteristics         Patients   \%
  ----------------------- ---------- ------
  Age                                
  ≤50                     784        55.6
  \>50                    627        44.4
  Gender                             
  Female                  68         11.9
  Male                    1243       88.1
  Tumor size                         
  ≤5cm                    543        38.5
  \>5cm                   868        61.5
  HBsAg                              
  Negative                179        12.7
  Positive                1231       87.2
  Cirrhosis                          
  NO                      497        35.2
  Yes                     914        64.8
  AFP (ng/ml)                        
  ≤20                     422        29.9
  \>20                    989        70.1
  Tumor number                       
  Single                  1113       78.9
  Multiple                298        21.1
  Tumor differentiation              
  I-II                    1169       82.8
  III-IV                  242        17.2
  TNM stage                          
  I                       848        60.1
  II-III                  563        39.9
  BCLC stage                         
  O-A                     527        37.3
  B-C                     884        62.7
  CHO (mmol/L)                       
  ≤ 4.42                  520        36.9
  \>4.42                  891        63.1
  TG (mmol/L)                        
  ≤ 1.06                  804        57
  \>1.06                  607        43
  LDL (mmol/L)                       
  ≤3.09                   701        49.7
  \>3.09                  710        50.3
  HDL (mmol/L)                       
  ≤ 0.88                  256        18.1
  \>0.88                  1155       81.9

###### 

Relationship between CHO Concentration and Clinical Characteristics in 1411 Patients With liver cancer.

  Characteristics         CHO≤4.420   CHO\>4.420   P
  ----------------------- ----------- ------------ -------
  Age                                              0.147
  ≤50                     302         482          
  \>50                    218         409          
  Gender                                           0.239
  Female                  55          113          
  Male                    465         778          
  Tumor size                                       0.357
  ≤5cm                    192         351          
  \>5cm                   328         540          
  HBsAg                                            0.621
  Negative                69          110          
  Positive                451         780          
  Cirrhosis                                        0.047
  NO                      166         331          
  Yes                     354         560          
  AFP (ng/ml)                                      0.104
  ≤20                     169         253          
  \>20                    351         638          
  Tumor number                                     0.286
  Single                  402         711          
  Multiple                118         180          
  Tumor differentiation                            0.059
  I-II                    422         743          
  III-IV                  98          148          
  TNM stage                                        0.463
  I                       306         542          
  II-III                  214         349          
  BCLC stage                                       0.349
  O-A                     186         341          
  B-C                     334         550          

###### 

Relationship Between HDL Concentration and Clinical Characteristics in 1411 Patients With liver cancer.

  Characteristics         HDL-C≤0.88   HDL-C\>0.88   P
  ----------------------- ------------ ------------- ---------
  Age                                                0.385
  ≤50                     136          648           
  \>50                    120          507           
  Gender                                             0.111
  Female                  23           145           
  Male                    233          1010          
  Tumor size                                         \<0.001
  ≤5cm                    62           481           
  \>5cm                   194          674           
  HBsAg                                              0.029
  Negative                43           136           
  Positive                213          1019          
  Cirrhosis                                          0.546
  NO                      86           411           
  Yes                     170          744           
  AFP (ng/ml)                                        0.262
  ≤20                     84           338           
  \>20                    172          817           
  Tumor number                                       0.506
  Single                  198          915           
  Multiple                58           240           
  Tumor differentiation                              0.180
  I-II                    204          961           
  III-IV                  52           194           
  TNM stage                                          
  I                       140          707           0.054
  II-III                  116          448           
  BCLC stage                                         \<0.001
  O-A                     59           467           
  B-C                     197          688           

###### 

Univariate and Multivariate Cox Proportional Analysis with Overall Survival.

                          Univariate Analysis   Multivariate Analysis                         
  ----------------------- --------------------- ----------------------- --------------------- ---------
  Parameter               HR (95% CI)           P                       HR (95% CI)           P
  Age                     1.086(0.941-1.254)    0.258                                         
  ≤50                                                                                         
  \>50                                                                                        
  Gender                  1.112(0.885-1.398)    0.360                                         
  Female                                                                                      
  Male                                                                                        
  Tumor size              2.088(1.782-2.447)    \<0.001                 2.297(1.217 -4.337)   0.01
  ≤50                                                                                         
  \>5cm                                                                                       
  HBsAg                   1.145(0.917-1.430)    0.233                                         
  Negative                                                                                    
  Positive                                                                                    
  Cirrhosis               1.057(0.908-1.230)    0.475                                         
  NO                                                                                          
  Yes                                                                                         
  AFP (ng/ml)             1.833(1.545-2.174)    \<0.001                 1.632 (1.372-1.941)   \<0.001
  ≤ 20                                                                                        
  \>20                                                                                        
  Tumor number            1.990(1.696-2.334)    \<0.001                                       
  Single                                                                                      
  Multiple                                                                                    
  Tumor differentiation   1.514(1.266-1.810)    \<0.001                 1.250(1.042-1.499)    0.016
  I-II                                                                                        
  III-IV                                                                                      
  TNM stage               2.405(2.081-2.779)    \<0.001                 2.017(1.673-2.430)    \<0.001
  I                                                                                           
  II-III                                                                                      
  BCLC stage              2.052(1.749-2.408)    \<0.001                                       
  O-A                                                                                         
  B-C                                                                                         
  CHO (mmol/L)            0.800(0.691-0.926)    0.003                   0.831(0.714-0.967)    0.017
  ≤4.42                                                                                       
  \>4.42                                                                                      
  TG (mmol/L)             0.908(0.785-1.049)    0.588                                         
  ≤1.06                                                                                       
  \>1.06                                                                                      
  LDL                     0.936(0.811-1.080)    0.364                                         
  ≤3.09                                                                                       
  \>3.09                                                                                      
  HDL                     0.679(0.570-0.808)    \<0.001                 0.790(0.658-0.948)    0.011
  ≤0.88                                                                                       
  \>0.88                                                                                      

###### 

Univariate and Multivariate Cox Proportional Analysis with Disease-Free-Survival.

                          Univariate Analysis   Multivariate Analysis                         
  ----------------------- --------------------- ----------------------- --------------------- ---------
  Parameter               HR (95% CI)           P                       HR (95% CI)           P
  Age                     1.049(0.920-1.197)    0.476                                         
  ≤50                                                                                         
  \>50                                                                                        
  Gender                  1.158(0.938-1.430)    0.173                                         
  Female                                                                                      
  Male                                                                                        
  Tumor size                                                                                  
  ≤5cm                    1.725(1.499-1.985)    \<0.001                 1.967(1.084-3.567)    0.026
  \>5cm                                                                                       
  HBsAg                   0.990(0.813-1.207)    0.924                                         
  Negative                                                                                    
  Positive                                                                                    
  Cirrhosis               1.003(0.873-1.151)    0.970                                         
  NO                                                                                          
  Yes                                                                                         
  AFP (ng/ml)             1.435(1.237-1.664)    \<0.001                 1.288 (1.107-1.498)   0.001
  ≤20                                                                                         
  \>20                                                                                        
  Tumor number            1.972(1.700-2.288)    \<0.001                                       
  Single                                                                                      
  Multiple                                                                                    
  Tumor differentiation   1.410(1.193-1.665)    \<0.001                 1.238(1.045-1.466)    0.014
  I-II                                                                                        
  III-IV                                                                                      
  TNM stage               2.324(2.034-2.654)    \<0.001                 2.023(1.703-2.403)    \<0.001
  I                                                                                           
  II-III                                                                                      
  BCLC stage              1.713(1.487-1.974)    \<0.001                                       
  O-A                                                                                         
  B-C                                                                                         
  CHO (mmol/L)            0.844(0.737-0.966)    0.012                   0.850(0.740-0.977)    0.022
  ≤ 4.42                                                                                      
  \>4.42                                                                                      
  TG (mmol/L)             0.964(0.844-1.101)    0.588                                         
  ≤ 1.06                                                                                      
  \>1.06                                                                                      
  LDL (mmol/L)            0.890(0.780-1.015)    0.082                                         
  ≤3.09                                                                                       
  \>3.09                                                                                      
  HDL (mmol/L)            0.778(0.659-0.918)    0.003                   0.899(0.758-1.067)    0.222
  ≤ 0.88                                                                                      
  \>0.88                                                                                      
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